Introduction
Lung cancer is one of the most common and deadly forms of human cancer with an estimated 172 000 new cases and 157 000 deaths in the USA anticipated for 2003 (Jemal et al., 2003) . Lung cancers include a broad variety of neoplasms classified as either small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC). SCLC comprises B20% of all lung cancers with NSCLC comprising the remaining B80%. NSCLC is further divided into adenocarcinoma (AC) (B30-35% of all cases), squamous cell carcinoma (SCC) (B30% of all cases), and large cell carcinoma (LCC) (B10% of all cases). Additional NSCLC subtypes, not as clearly defined in the literature, include adenosquamous cell carcinoma (ASCC) and bronchioalveolar carcinoma (BAC).
Several technologies are being utilized for gene expression profiling in cancer, including: serial analysis of gene expression (SAGE) (Velculescu et al., 1995) , DNA microarrays (DeRisi et al., 1996) , oligonucleotide microarrays (Lockhart et al., 1996) , and suppression subtractive hybridization (SSH) (Diatchenko et al., 1996) . Independently, each of these techniques can be effective in identifying differentially expressed genes. Indeed, a significant number of genes dysregulated in NSCLC have been previously identified using various methodologies, including: SAGE (Nacht et al., 2001) , DNA arrays (Bhattacharjee et al., 2001; Garber et al., 2001; Beer et al., 2002; Heighway et al., 2002) , and SSH (Bangur et al., 2002) . Nevertheless, there remains a critical need for identifying additional lung cancerassociated genes for further understanding of the disease pathobiology and ultimately to provide new diagnostic and therapeutic options for patients with NSCLC.
In this study, we combine the use of SSH and cDNA arrays for identifying a set of NSCLC-associated genes. Our data demonstrate the effectiveness of combining SSH and expression profiling in identifying NSCLCspecific genes. By using pools of NSCLC cell lines and a mixture of normal tissues in our subtraction protocol, we successfully enriched for unique tumor-selective genes expressed across subsets of the disease while eliminating common or redundant sequences. We report the identification of NSCLC-specific genes from several distinct functional categories. Tumor selectivity for a subset of these genes was further validated by independent assays using tumor cell lines and patient tissue samples. The potential utility of these genes for diagnosis and therapeutic targeting of NSCLC, and other cancers, awaits further investigation.
Results

Construction and evaluation of NSCLC-specific cDNA libraries
Two SSH cDNA libraries, NSCLC-lib1 and NSCLClib2, were constructed starting from pools of poly(A) þ RNA from multiple NSCLC cell lines and subtracted with pools of RNA from multiple normal patient tissues. Briefly, NSCLC-lib1 and NSCLC-lib2 utilized four (A549, H23, H226, and H460) and six (A549, H23, H920, H969, H358, and H650) NSCLC cell lines, respectively, as sources of 'tester' RNA. As for the 'driver' RNA used for subtraction, NSCLC-lib1 utilized five (colon, kidney, liver, lung, and pancreas) and NSCLC-lib2 utilized eight (colon, kidney, liver, lung, pancreas, spleen, stomach, and heart) pools of RNA from normal patient tissue. Subtraction efficiency and overall library quality were assessed by PCR depletion of the known housekeeping genes G3PDH and atubulin. PCR products for G3PDH and a-tubulin were visible after 20 and 25 cycles of amplification for unsubtracted cDNA pools, respectively, and after 30 amplification cycles for both subtracted cDNA pools. Thus the commonly expressed genes, G3PDH and atubulin, are significantly depleted from the subtracted cDNA mixtures.
Prescreening by colony PCR of a total of 96 random clones from NSCLC-lib 1 and NSCLC-lib 2 confirmed a high (490%) overall cloning efficiency with an insert size range between 500 and 2000 bp. Sequence analysis of 40 random clones, 20 each from NSCLC-lib 1 and NSCLC lib-2, yielded a complex mixture of previously identified cancer-associated genes as well as a unique set of previously uncharacterized genes with a low level of redundancy. These data are consistent with significant enrichment for tumor-associated genes within both NSCLC libraries.
Expression profiling and identification of NSCLC genes
A total of 3072 clones from NSCLC-lib 1 and NSCLClib 2 were prescreened by colony PCR. Clones with no, small (o500 bp), or multiple inserts were eliminated in amplifying clones to be used for array comparisons. Evaluation of genes that are differentially expressed in NSCLC was undertaken using ArrayVision 6.0 as described by others (Ji et al., 2003) . Tumor (T) : normal (N) ratios were calculated based on the average intensity of duplicate spots following background subtraction and subsequent normalization to control 'housekeeping' gene, EF-1.
Expression profiling identified genes that were overexpressed in NSCLC including 13 genes overexpressed X10-fold, 66 genes X4-fold, and 147 genes X2-fold. These 147 putative NSCLC-associated genes are predicted to encode many different functional classes of proteins including enzymes (n ¼ 33), cell cycle regulators (n ¼ 21), ribosomal proteins (n ¼ 15) as well as genes of unknown function (n ¼ 26) (Figure 1) .
Literature searches for each of the 147 NSCLCassociated genes were conducted using PubMed (www.ncbi.nlm.nih.gov/PubMed/) and a combination of search terms including 'gene name' together with 'non-small cell lung cancer', or 'cancer' (Table 1) . To broaden our search for prior 'cancer association', Unigene cluster 'Hs.' designations for L1-L19 were used to query public SAGE (Lash et al., 2000) (http:// www.ncbi.nlm.nih.gov/SAGE/), and SOURCE (Diehn et al., 2003) (http://source.stanford.edu) databases (Table 1) . Briefly, no prior cancer-association was found for three genes (L7, L10, L15), nine genes (L2, L3, L4, L6, L8, L12, L13, L14, L16) have been previously associated with cancers other than NSCLC and seven genes (L1, L5, L9, L11, L17, L18, L19) have prior NSCLC association (Table 2) .
Of the 147 genes overexpressed by X2-fold in NSCLC cell lines, 30 have not been previously published in association with any neoplasm (Table 1) . Of the 147 genes, 65 have been associated with cancers other than NSCLC. The validity of our gene identification strategy is supported by the observation that 52 of the 147 genes identified have previously been associated with NSCLC by others using alternative methodologies (Table 1) . These previously known NSCLC-associated genes include: PGP9.5 (Hibi et al., 1999) , cytokeratin 18 (Corson and Pinkus, 1982) , aldehyde dehydrogenase 1 (Schnier et al., 1999) , LDHA (Beer et al., 2002) , and aldo-keto reductase 1 (Palackal et al., 2002) . LDHA, displaying the highest recovery frequency at 51, was previously associated with c-Myc-induced transformation (Lewis et al., 2000) . LDHA-specific probes were used as controls to prescreen expression arrays to estimate clone redundancy.
Prediction of subcellular location of NSCLC gene products
Unigene cluster designations were used to retrieve the predicted amino-acid sequences corresponding to each of the putative NSCLC-associated genes identified ( Table 1 ). The subcellular location of the putative NSCLC-associated proteins was then predicted using the program PSORT II (Horton and Nakai, 1997) (Table 1) . Genes were predicted to encode proteins associated with the cytoplasm (n ¼ 63), nucleus (n ¼ 54), plasma membrane (n ¼ 10), mitochondria (n ¼ 10), endoplasmic reticulum (n ¼ 8). or extracellular matrix (n ¼ 2). Table 1 ) 
QPCR analysis of NSCLC genes
QPCR was used as an independent method to probe the association of identified genes with NSCLC tumor cell lines and extend the observations to patient samples.
QPCR data are reported as T : N ratios calculated using the comparative threshold cycle (C t ) method (Aarskog and Vedeler, 2000) after normalization to a control housekeeping gene, EF-1 (Table 3) . Primary human SAE cells were used to provide a 'normal' sample to Recovery frequency is the number of times each clone was identified in array analysis c Identity, Unigene ID, and chromosomal localization were assigned using the NCBI database (www.ncbi.nlm.nih.gov/)
d Subcellular location was predicted using PSORT II (Horton and Nakai, 1997): C, cytoplasm; EM, extracellular matrix; ER, endoplasmic reticulum; M, mitochondria; N, nucleus; PM, plasma membrane Table  1 . Not shown are genes L7, L10, and L15 as they lack prior cancer association d SAGE data is reported using a minimum of 100 tags/million e SOURCE tumor data is reported using the 'carcinoma classification' data set (Su et al., 2001) . Gene expression ratios 42 : 1 are reported f SOURCE cell line data is reported using the 'NCI60' data set (Ross et al., 2000) . Gene expression ratios 42 Â for tumor cell lines versus reference pools are reported Expression profiling in NSCLC J Petroziello et al compare with the NSCLC cell lines. In the case of patient samples, adjacent normal tissue was used as a source of RNA for comparison. For this and subsequent studies described herein, we focused on five of the 'L' genes, namely, L4, L5, L7, L11, and L16. These genes span a range of T : N ratios (2.3-6-fold) and were chosen as representative examples of the 19 genes with no prior Unigene cluster designation based on combined NSCLC selectivity and low transcript levels in normal tissues. CXC5 was included as a positive control gene based on its previously reported association with lung cancer (Arenberg et al., 1998) . Genes L4, L5, L7, L11, and L16 were found to be upregulated by X2-fold in at least three of 11 cell lines tested including one to three of seven cell lines used in the construction of either NSCLC-lib1 or NSCLC-lib2. Moreover, these five different genes were found to be upregulated in cell lines representing at least three different subtypes of NSCLC (Table 3 ). In addition, each of these five putative NSCLC-associated genes was found to be upregulated by X2-fold in at least four out of eight patient samples including SCC and AC.
Cancer profiling array (CPA) analysis of NSCLC genes A CPA was used as an additional independent validation tool to explore the potential upregulation of genes L4, L5, L7, L11, and L16 in lung and other common tumors. Again, the previously reported NSCLC associated gene, CXC5 (Arenberg et al., 1998) , was utilized as a positive control. The housekeeping gene EF-1 was used as a positive control to evaluate sample loading equivalence.
NSCLC-specific expression was evaluated using 21 paired samples (Table 4 ). L4 and L5 are upregulated by X2-fold in SCC but not other NSCLC tested. In contrast, L7, L11, and L16 are overexpressed in each of the NSCLC subtypes examined. In addition to NSCLC, another 206 patient samples from multiple tumor types were also evaluated using the CPA (Figure 2 ). All five genes tested were upregulated by X2-fold in X20% of tumor samples from other organs: L4 in colon, ovary, rectum, and stomach; L5 in kidney, ovary, uterus, and stomach; L7 in uterus; L11, breast and uterus; and L16 in breast, colon, ovary, uterus, and stomach.
Experimental determination of subcellular localization of NSCLC gene products
Based on favorable expression data, subcellular localization patterns were evaluated for a subset of the NSCLC genes using N-terminal GFP constructs and fluorescent microscopy ( Figure 3) . Genes displaying the most interesting tumor-specific expression levels were prioritized for these localization studies. Candidate genes were expressed in tandem with GFP in both Nterminal and C-terminal orientations and subsequently visualized with consistent patterns observed by fluorescent microscopy. Experimental localization results were compared with previously described data sets (Simpson et al., 2000) . L11 and L16 displayed cellular localization consistent with nuclear staining, as pre- (Arenberg et al., 1998) a QPCR data were analysed using the comparative C t method (Aarskog and Vedeler, 2000) Briefly, the differential expression of NSCLC target gene versus the housekeeping gene was first calculated for tumor and nontumor samples using the expression: DC t ¼ C t NSCLC target -C t EF-1 . Next, tumor : normal ratios were calculated from the DC t values for tumor and normal samples: tumor/normal ¼ 2 (DCt Tumor-DCt Normal) . SAE cells were used to provide a 'normal' sample to compare with the NSCLC cell lines. In the case of patient samples, adjacent normal tissue was used as a source of RNA for comparison. Tumor : normal values X2 are in bold b Tumors types: AC, adenocarcinoma; ASCC, adenosquamous cell carcinoma; SCC, squamous cell carcinoma; LCC, large-cell carcinoma; and BAC, bronchioalvoelar carcinoma c Cell lines used in construction of NSCLC-lib1 or NSCLC-lib-2
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CDART domain architecture analysis for NSCLC genes
Amino-acid sequences corresponding to the NSCLCassociated genes L1-L19 (Genbank accession numbers AAT06731-AAT06749, respectively) were aligned and analysed by comparison with known protein domains using CDART (Geer et al., 2002) (Table 5 ). L9 contains a carboxy-terminal LIM domain previously associated with DNA binding (Perez-Alvarado et al., 1994) . L16 contains a BROMO domain believed to recognize acetylated residues and likely participate in cell signaling (Kouzarides, 2000) . Seven L genes (L1, L2, L6, L7, L12, L13, and L18) contain protein domains whose biologic functions have yet to be reported (Table 5 ). The remaining 10 'L' genes have no homology with existing protein domain sequences. (Geer et al., 2002) b See Table 1 . Not shown are genes L3, L4, L5, L8, L10, L11, L15, L16, L17, and L19 as no homology with known protein domain sequences was detected c GenBank Accession numbers AAT06731-AAT06749 were assigned for amino-acid sequences corresponding to sequences L1-L19, respectively.
d CD e Domain name f Function as assigned using the CDART resource at NCBI Figure 2 CPA analysis of L4, L5, L7, L11, and L16 in additional tumor types: breast (n ¼ 50), colon (n ¼ 34), renal (n ¼ 20), ovarian (n ¼ 14), uterus (n ¼ 42), rectal (n ¼ 18), and gastric (n ¼ 28). Differential expression levels are reported as percentage X2-fold tumor : normal. CXC-5 was selected as a positive control based on previous reports (Arenberg et al., 1998) Figure 3 Subcellular localization studies using N-terminal GFP reporter constructs and fluorescence microscopy. Experiments revealed staining consistent with the following localization patterns: focal adhesion sites (L4), cytoplasm (L7), and nuclear (L11 and L16)
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Discussion
SSH is a powerful technique used to identify interesting differentially expressed transcripts (Diatchenko et al., 1996) and has been previously used in identifying genes associated with various neoplasms including carcinomas of the kidney (Stassar et al., 2001) , liver (Miyasaka et al., 2001) , prostate (Porkka and Visakorpi, 2001), colon (Hufton et al., 1999) , breast (Yang et al., 1999) , and lung (Bangur et al., 2002) . In this report, we combine SSH and expression array profiling to identify a new set of NSCLC-associated genes. Quantitative PCR and CPAs were used to confirm overexpression for some of the most interesting genes. These independent validation tools provided additional expression data for multiple tumor types. A set of 30 genes was identified that has not previously been associated with any neoplasm. In addition, we identified a set of 19 genes with no prior named Unigene cluster designation, named herein as L1-L19. Subsequent analysis was focused on five of the identified NSCLC-associated genes, namely L4, L5, L7, L11, and L16, as representative examples based on our observed tumor overexpression and minimal sequence homology with previously 'identified' genes. Our experimental and in silico observations for the five most promising genes confirmed tumor selectivity in multiple carcinoma types including: L4 (lung, colon, ovarian, rectal, and gastric); L5 (lung, brain, breast, renal, ovarian, prostate, gastric, and uterine); L7 (lung, breast, renal, and uterine); L11 (lung, breast, colon, ovarian, pancreatic, prostate, and uterine); and L16 (lung, breast, colon, ovarian, gastric, and uterine). These data, utilizing a combination of NSCLC-specific expression arrays, QPCR assays, and CPAs, confirmed the success of our combined method in identifying a set of tumorselective targets.
Unigene cluster designations were used along with the NCBI online Mendelian Inheritance In Man Gene Map in assigning chromosomal locations for each NSCLC gene. Comparative genomic hybridization has identified chromosomal arms 3q, 5p, 7p, and 8q as being commonly over-represented in NSCLC (Balsara et al., 1997) . In a SAGE transcriptome-based study, several over-represented chromosomal regions were identified including those associated with the SCC subtype in arm 1q, 3q, 5p, 7p, and 8q . Of the 19 identified NSCLC-associated genes, three map to those previously described NSCLC-specific chromosomal regions: genes L1, and L16 (8q), and gene L6 (5p). In addition, other notable regions included: L3, L13, and L14 (17q), genes L2 and L10 (14q), and genes L11 and L12 (16p).
We also identified a set of 65 genes associated with NSCLC that had previously only been associated with cancers other than NSCLC (Table 1) . Among these genes, keratin hair basic 1 protein (Cribier et al., 2001) displayed the highest NSCLC-specific expression. CSE1 is an apoptosis regulator (Brinkmann et al., 1995) . Pituitary tumor-transforming gene (PTTG1) is elevated in multiple tumors and induces in vitro transformation and in vivo tumor formation (Zhang et al., 1999) . Epiregulin is overexpressed in epidermoid carcinoma and functions by stimulating cancer cell growth (Toyoda et al., 1995) . Nucleolin is a transcriptional activator of HPV-18 in cervical cancer (Grinstein et al., 2002) . LDB1 is overexpressed in oral carcinoma (Mizunuma et al., 2003) . Ribosomal proteins RPL8 (Tarantul et al., 2000) , RPS13 (Denis et al., 1993) , RPL5 (Frigerio et al., 1995) , RPL23A (Jiang et al., 1997) , RPL19 (Henry et al., 1993) , RPL37 (Loging and Reisman, 1999) , and RPS16 (Batra et al., 1991) are previously reported in association with multiple cancers other than NSCLC. Our data illustrate the success of our approach in discovering previously unidentified NSCLC-specific genes. The biological role or potential therapeutic utility for this category of identified genes remains to be evaluated.
The overall effectiveness of our discovery approach and complexity of our gene lists was further validated by our success in identifying genes that have previously been associated with NSCLC. Of the 52 previously described NSCLC-associated genes in our list, LDHA (Beer et al., 2002) was the most abundant. PGP9.5 has been previously described as highly overexpressed in NSCLC (Hibi et al., 1999) . PGP9.5 is a ubiquitin hydrolase expressed in neuronal tissues (Wilkinson et al., 1989) with a potential role in cancer development by contributing to the growth of somatic cells by increasing deubiquitination of cyclins (Spataro et al., 1998) . CXC5 is an angiogenic factor in NSCLC (Arenberg et al., 1998) . Cysteine-rich protein 61 functions as a tumor suppressor gene in NSCLC (Tong et al., 2001) . Cytokeratin 7 (Loy and Calaluce, 1994) as well as cytokeratin 8 and cytokeratin 18 (Corson and Pinkus, 1982) have been described as potential markers for NSCLC. Leukocyte antigens CD98 (Rintoul et al., 2002) , CD29 (Oshita et al., 2002) , CD59 (Niehans et al., 1996) , and ITGB5 (Smythe et al., 1995) are proposed lung cancer-associated targets. Cyclin B1 is an early stage marker for NSCLC (Soria et al., 2000) , and splicing factor 3, CCT7, CCT5, and YWHAG were previously identified using NSCLC-specific arrays (Kikuchi et al., 2003) .
We have successfully utilized a combination of cDNA subtraction and expression array profiling to identify several interesting cancer-associated genes. We report the evaluation of 43000 clones and subsequent identification of 147 NSCLC-specific genes including 30 lacking previously published cancer association. These 30 genes warrant further investigation to assess any potential for the diagnosis, prognosis, and therapy of NSCLC and other cancers.
Materials and methods
Cell lines and patient tissues
NSCLC cell lines were obtained from the American Type Culture Collection (ATCC, Manasas, VA, USA). Normal SAE cells were obtained from Clonetics (San Diego, CA, USA). Normal tissue total and poly(A)
þ RNA used in preparing SSH libraries was purchased from Origene (RockExpression profiling in NSCLC J Petroziello et al ville, MD, USA), Biochain, (Hayward, CA, USA), and Clontech (Palo Alto, CA, USA). NSCLC tumor and adjacent normal patient tissue RNA used for QPCR experiments was purchased from Biochain and Clontech.
RNA isolation
Total RNA was isolated using RNA-Bee (Tel-Test, Friendswood, TX, USA). Poly(A) þ RNA was isolated using the Oligotex kit (Qiagen, Valencia, CA, USA).
Construction of SSH cDNA libraries
Two NSCLC subtracted cDNA libraries, NSCLC-lib1 and NSCLC-lib2, were constructed using the PCR-select kit (Clontech). NSCLC-lib 1 was constructed using poly(A) þ RNA from four NSCLC cell lines (A549, H23, H226, and H460) as tester and a pool of five normal patient tissue (colon, kidney, liver, lung, and pancreas) poly(A)
þ RNA in equal amounts as driver. NSCLC-lib 2 was constructed using poly(A) þ RNA from six NSCLC cell lines (A549, H23, H920, H969, H358, and H650) as tester and a pool of eight normal patient tissue (colon, kidney, liver, lung, pancreas, spleen, stomach, and heart) poly(A)
þ RNA in equal amounts as driver. Tester and driver cDNAs were synthesized from 2 mg poly(A) þ RNA using cDNA synthesis primer 5 0 -TTT TGT ACA AGC TT 30 N 1 N-3 0 (where N ¼ A, T, G, or C) and Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). RsaI digested tester cDNA was ligated to adaptor 1 (5 0 -CTA ATA CGA CTC ACT ATA GGG CTC GAG CGG CCG CCC GGG CAG GT-3 0 ) and adaptor 2R (5 0 -CTA ATA CGA CTC ACT ATA GGG CAG CGT GGT CGC GGC CGA GGT-3 0 ) using T4 DNA ligase (Invitrogen). Driver cDNA (600 ng) was added to each of the two tubes containing adaptor-1-ligated tester (20 ng) and adaptor 2R-ligated tester (20 ng). The reaction mixture was denatured at 951C for 1.5 min and then incubated at 681C for 8 h. The samples were then combined with excess heat-denatured driver cDNA (150 ng) and incubated overnight at 681C.
Primary PCR was performed using PCR primer 1 (5 0 -CTA ATA CGA CTC ACT ATA GGG C-3 0 ) with cycling conditions: 751C for 7 min, 941C for 2 min, 27 cycles at 941C for 30 s, 661C for 30 s, 721C for 1.5 min, and followed by a final extension at 721C for 5 min. Secondary PCR was performed using PCR primers NP1 (5 0 -TCG AGC GGC CGC CCG GGC AGG T-3 0 ) and NP2R (5 0 -AGC GTG GTC GCG GCC GAG GT-3 0 ) with cycling conditions: 941C for 2 min; 12 cycles at 941C for 30 s, 681C for 30 s, and 721C for 1.5 min; and a final extension at 721C for 5 min.
Cloning and sequence analysis of NSCLC genes NSCLC cDNA pools were cloned into pCR4-TOPO vectors (Invitrogen) and transformed into chemically competent TOP 10 cells (Invitrogen). NSCLC clones were screened by colony PCR with 490% efficiency. DNA isolations were performed for positive clones using Plasmid kits (Qiagen). DNA sequencing was performed using the ABI377 (Perkin Elmer/ Applied Biosystems, Foster City, CA, USA), with universal M13F and M13R primers. DNA homology database searches were performed using the NBLAST algorithm. Overall library redundancy and complexity was evaluated based on the frequency of unique clones recovered. Highly redundant clones were used as probes to prescreen the libraries prior to array generation.
Expression array screening and analysis
A total of 3072 combined cDNA inserts from NSCLC-1 and NSCLC-2 libraries were PCR amplified using M13F and M13R universal primers. Amplified clones were visualized using 1.5% agarose gels and stained with ethidium bromide. PCR products were purified using 96-well purification plates (Millipore, Bedford, MA, USA) and spotted in equal concentrations (2 ng/spot) onto nylon membranes (Hybond-XL, Amersham Pharmacia Biotech, Piscataway, NJ, USA), using the Biomek 2000 Laboratory Automation Workstation (Beckman Coulter, Fullerton, CA, USA). Membranes were denatured in 1 M NaOH, 2 M NaCl, and 25 mM EDTA, neutralized in 2 Â SSC, and UV crosslinked.
Array hybridizations were performed using poly(A) þ RNA converted to cDNA using Superscript II RT (Invitrogen) and labeled with [a- 32 P]dCTP (Amersham). Hybridizations were performed overnight at 421C in 6 Â SSC, 0.1% SDS, 50% formamide, and 5 Â Denhardt's solution (Research Genetics, Huntsville, AL, USA). Membrane wash conditions included four times with 2 Â SSC/0.1% SDS for 10 min at room temperature followed by four times with 0.1 Â SSC/0.1% SDS for 30 min at 651C.
Array differentials were calculated using PhosPhorImager SI (Molecular Dynamics, Sunnyvale, CA, USA) and Array Vision 6.0 software (Imaging Research, St. Catharines, ON, CA, USA). Housekeeping control genes b-actin, EF-1, a-tubulin, and cyclophilin were used to assess hybridization signal equivalence. Quantitative differentials were calculated based on normalization with EF-1a. The reproducibility of expression array screening was ensured by the inclusion of duplicate controls at various locations on the membrane. In addition, several previously described NSCLC genes were identified multiple times throughout the screening process.
QPCR
QPCR analysis was performed using TaqMan TM MGB chemistry (Perkin Elmer/ABI (PE Biosystems, Foster City, CA, USA) containing a reporter dye at the 5 0 end (FAM) and a nonfluorescent quencher (NFQ) at the 3 0 end in designing genespecific primers. In comparing quantitative expression differentials, a panel of tumor and adjacent normal tissues and cell line RNA samples were utilized. In addition, each sample was run in duplicate to ensure quantitative accuracy. QPCR data are reported as T : N ratios and calculated using the comparative threshold cycle (C t ) method (Aarskog and Vedeler, 2000) . Briefly, the differential expression of NSCLC target gene versus the housekeeping gene, EF-1, was first calculated for tumor and nontumor samples using the expression:
Next T : N ratios were calculated from the DC t values for tumor and normal samples:
Tumor=Normal ¼ 2 ðDCttumorÀDCtnormalÞ SAE cells were used to provide a 'normal' sample to compare with the NSCLC cell lines. In the case of patient samples, adjacent normal tissue was used as a source of RNA for comparison. All reported QPCR reactions were performed and analysed using an ABI 7000 SDS system (PE Biosystems).
CPAs CPA (Clontech) were used in calculating differential expression levels using multiple tumor and adjacent normal tissues. Hybridization signal intensities were analysed using ArrayVision 6.0 (Imaging Research). The housekeeping control gene, EF-1, was used in evaluating the equivalence of sample loading.
Full-length cloning and subcellular localization
NSCLC candidate gene open reading frames (ORFs) were directionally cloned into pENTR/D-TOPO s Gateway TM vectors (Invitrogen). The 5 0 gene-specific primers were selected to include the initiator ATG and 3 0 gene-specific primers to include the C-terminal amino acid, but leaving out the termination triplet sequence. A set of 19 genes with no prior Unigene cluster designation, named L1-L19, were submitted to GenBank and assigned Accession numbers AY598320-AY598338, respectively. Constructs were then transiently transfected into tsA-201 cells using FuGENE 6 reagent (Roche, Indianapolis, IN, USA). Subcellular localization patterns for a subset of NSCLC candidate genes were monitored by fluorescent microscopy and compared with previously described data sets (Simpson et al., 2000) . Each of the NSCLC candidate genes displayed consistent results with both N-terminal and C-terminal green fluorescent protein (GFP) tags.
Abbreviations AC, adenocarcinoma; ASCC, adenosquamous cell carcinoma; BAC, bronchioalveolar carcinoma; CPA, cancer profiling array; GFP, green fluorescent protein; LCC, large-cell carcinoma; NSCLC, non-small-cell lung cancer; QPCR, quantitative real-time PCR; SAGE, serial analysis of gene expression; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer; SSH, suppression subtractive hybridization.
